Can an AI chatbot ease the aftermath of cancer?

NCT ID NCT07772596

NEW Not yet recruiting Symptom relief Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational support. The goal is to see if the chatbot is acceptable, usable, and engaging enough to be a helpful tool.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI-powered supportive care chatbot
What this could lead to: If successful, this could point toward a scalable, accessible tool to help young adult cancer survivors manage lingering symptoms and improve their quality of life after treatment.
What could go wrong: This is a small pilot study focused on feasibility, not effectiveness. The chatbot may not be engaging enough, and results may not generalize beyond this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.